BioSpace News Archive

Miromatrix Medical Inc., a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, announced that the Company will be added to the Russell Microcap® Index, effective after the U.S. market, September 20, 2021.

Landos Biopharma, Inc. announced a research collaboration with the Icahn School of Medicine at Mount Sinai to conduct a Phase 2 trial of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, in patients with moderate-to-severe Crohn’s disease.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET.

OpSens Inc., a cardiology medical device company providing innovative product solutions based on its patented optical technology, announced that it has received Health Canada approval to commence the first in-man study with its SavvyWire, a guidewire developed specifically for transcatheter aortic valve replacement.

Ranok Therapeutics to Present its CHAMP™ Platform at 19th Annual Discovery on Target Conference

BeiGene added to FTSE Global Equity Index Large Cap, All-World (LM), All-Cap (LMS), Total-Cap (LMSµ); as well as the Developed ESG Low Carbon Select Index and Asia ex Japan ESG Low Carbon Select Index

Mirati Therapeutics, Inc. today announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation following prior systemic therapy.

OSE Immunotherapeutics today announced that the positive final results of its Phase 3 trial of neoepitope-based cancer vaccine Tedopi ® , called Atalante 1, in HLA-A2 positive patients with advanced non-small cell lung cancer

Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment) successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) of patients with metastatic colorectal cancer (mCRC) of the liver.

Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan ® /Reeqonus™ for COVID-19 Patients